PALBOCICLIB (Ibrance) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires Kinase Inhibitor prior-authorization documentation for PALBOCICLIB (Ibrance): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Humana reviews PALBOCICLIB (Ibrance) prior authorizations against its medical policy for Kinase Inhibitor. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Kinase Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Humana's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
PALBOCICLIB (Ibrance)-specific denial patterns and context
Across payers (not just Humana), PALBOCICLIB (Ibrance)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring endocrine monotherapy first
- Combination partner not formulary (specific AI denied)
- Continuation beyond progression denied
- Specialty pharmacy network restriction
Brand: Ibrance. CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer. First-in-class. PALOMA trial series. Loss of exclusivity expected ~2027.
Manufacturer patient-assistance program: Pfizer Oncology Together — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
How Humana approaches Specialty pharmacy drugs PAs
Humana's Specialty pharmacy drugs reviewer typically anchors PALBOCICLIB (IBRANCE) prior-auth decisions on ma plan step therapy on part b drugs and prior auth on specialty drugs. Pharmacy-benefit review for PALBOCICLIB (IBRANCE) at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Humana routes specialty-pharmacy denials through a separate appeal queue from medical-benefit denials — verify the appeal goes to the correct queue or it can be administratively denied for "wrong path". Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Heavily Medicare Advantage focused.
If the PA is denied
Humana gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus a peer-reviewed citation supporting PALBOCICLIB (Ibrance)for the patient's indication.
Medicare Advantage path: if Humana misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Humana as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For PALBOCICLIB (IBRANCE), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for PALBOCICLIB (Ibrance) prior auth?
Humana's typical PA packet for PALBOCICLIB (Ibrance): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Kinase Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Humana?
Standard PALBOCICLIB (Ibrance) PA decisions at Humana: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Humana most often reject PALBOCICLIB (Ibrance) for?
Across Humana's book the common rejection patterns include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. For PALBOCICLIB (Ibrance) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Which specialty pharmacy will Humana require for PALBOCICLIB (IBRANCE)?
Humana contracts with a specific specialty-pharmacy network — using an out-of-network specialty pharmacy is a common denial cause that is administrative rather than medical-necessity. Call the prior-auth line on the back of the member card to confirm the in-network specialty pharmacy for PALBOCICLIB (IBRANCE) before submission. Note that REMS-restricted PALBOCICLIB (IBRANCE) variants (where applicable) further narrow the in-network pharmacy list. Pharmacy-benefit handling is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). External-review escalation for Humana fully-insured policies sits with the KY insurance department.
How do I prep for a peer-to-peer with Humana on PALBOCICLIB (Ibrance)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the PALBOCICLIB (Ibrance) PA packet
Open ApprovalHelp — generate a PALBOCICLIB (Ibrance) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com